Sarrazin M, Poncin I, Fourquet P, Audebert S, Camoin L, Denis Y
J Biomed Sci. 2024; 31(1):103.
PMID: 39623375
PMC: 11613490.
DOI: 10.1186/s12929-024-01091-w.
Butler M, Vollmer W, Goodall E, Capon R, Henderson I, Blaskovich M
ACS Infect Dis. 2024; 10(10):3440-3474.
PMID: 39018341
PMC: 11474978.
DOI: 10.1021/acsinfecdis.4c00218.
Pais J, Antoniuk O, Pires D, Delgado T, Fortuna A, Costa P
Pharmaceuticals (Basel). 2024; 17(5).
PMID: 38794178
PMC: 11124399.
DOI: 10.3390/ph17050608.
Delgado T, Pais J, Pires D, Estrada F, Guedes R, Anes E
Pharmaceuticals (Basel). 2024; 17(5).
PMID: 38794129
PMC: 11124350.
DOI: 10.3390/ph17050559.
Pieren M, Abaigar Gutierrez-Solana A, Antonijoan Arbos R, Boyle G, Davila M, Davy M
J Antimicrob Chemother. 2024; 79(6):1353-1361.
PMID: 38656557
PMC: 11144484.
DOI: 10.1093/jac/dkae107.
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.
Dartois V, Dick T
Nat Rev Drug Discov. 2024; 23(5):381-403.
PMID: 38418662
PMC: 11078618.
DOI: 10.1038/s41573-024-00897-5.
Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug-resistant .
Harrison G, Wang E, Cho K, Mreyoud Y, Sarkar S, Almqvist F
mBio. 2024; 15(3):e0296823.
PMID: 38294237
PMC: 10936210.
DOI: 10.1128/mbio.02968-23.
Targeting iron-scavenging tools: a recent update on siderophores inhibitors.
Kumar G, Adhikrao P
RSC Med Chem. 2023; 14(10):1885-1913.
PMID: 37859726
PMC: 10583813.
DOI: 10.1039/d3md00201b.
: Pathogenesis and therapeutic targets.
Yang J, Zhang L, Qiao W, Luo Y
MedComm (2020). 2023; 4(5):e353.
PMID: 37674971
PMC: 10477518.
DOI: 10.1002/mco2.353.
Antibiotics in the clinical pipeline as of December 2022.
Butler M, Henderson I, Capon R, Blaskovich M
J Antibiot (Tokyo). 2023; 76(8):431-473.
PMID: 37291465
PMC: 10248350.
DOI: 10.1038/s41429-023-00629-8.
The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.
Singh V, Dziwornu G, Chibale K
Nat Rev Chem. 2023; 7(5):340-354.
PMID: 37117810
PMC: 10026799.
DOI: 10.1038/s41570-023-00472-3.
Omics analysis of Mycobacterium tuberculosis isolates uncovers Rv3094c, an ethionamide metabolism-associated gene.
Wan L, Hu P, Zhang L, Wang Z, Fleming J, Ni B
Commun Biol. 2023; 6(1):156.
PMID: 36750726
PMC: 9904262.
DOI: 10.1038/s42003-023-04433-w.
Chenodeoxycholic Acid-Amikacin Combination Enhances Eradication of Staphylococcus aureus.
Cui K, Yang W, Liu Z, Liu G, Li D, Sun Y
Microbiol Spectr. 2023; 11(1):e0243022.
PMID: 36625660
PMC: 9927322.
DOI: 10.1128/spectrum.02430-22.
Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases.
Dam S, Tangara S, Hamela C, Hattabi T, Faion L, Carre P
J Med Chem. 2022; 65(24):16651-16664.
PMID: 36473699
PMC: 9791652.
DOI: 10.1021/acs.jmedchem.2c01493.
Increased Susceptibility of to Ethionamide by Expressing PPs-Induced Rv0560c.
Seo H, Kim S, Mahmud H, Sultana O, Lee Y, Yoon Y
Antibiotics (Basel). 2022; 11(10).
PMID: 36290007
PMC: 9598822.
DOI: 10.3390/antibiotics11101349.
"Upcycling" known molecules and targets for drug-resistant TB.
Roubert C, Fontaine E, Upton A
Front Cell Infect Microbiol. 2022; 12:1029044.
PMID: 36275029
PMC: 9582839.
DOI: 10.3389/fcimb.2022.1029044.
Benzoic Acid Derivatives as Prodrugs for the Treatment of Tuberculosis.
Pais J, Magalhaes M, Antoniuk O, Barbosa I, Freire R, Pires D
Pharmaceuticals (Basel). 2022; 15(9).
PMID: 36145340
PMC: 9502840.
DOI: 10.3390/ph15091118.
How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance.
Maitre T, Morel F, Brossier F, Sougakoff W, Jaffre J, Cheng S
Microorganisms. 2022; 10(7).
PMID: 35889155
PMC: 9316172.
DOI: 10.3390/microorganisms10071436.
Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants.
Yu B, Roy Choudhury M, Yang X, Benoit S, Womack E, Lyles K
ACS Infect Dis. 2022; 8(8):1491-1508.
PMID: 35801980
PMC: 11227883.
DOI: 10.1021/acsinfecdis.2c00121.
CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis.
Li S, Poulton N, Chang J, Azadian Z, DeJesus M, Ruecker N
Nat Microbiol. 2022; 7(6):766-779.
PMID: 35637331
PMC: 9159947.
DOI: 10.1038/s41564-022-01130-y.